We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,307

Allegations of Invalidity Found Justified on the Basis of Obviousness
  • Borden Ladner Gervais LLP
  • Canada
  • February 15 2017

In this case, the Federal Court dismissed an application for an order of prohibition. The patent at issue claimed pharmaceutical formulations of


Dentons' pick of global regulatory trends to watch in 2017
  • Dentons
  • Australia, Canada, China, European Union, Germany, Mexico, OECD, United Kingdom, USA
  • February 9 2017

Dentons’ team of regulatory lawyers from key jurisdictions around the world weigh in on regulatory trends to watch in 2017 in the US, Europe, the UK


Competitionantitrust law
  • Dentons
  • USA, Canada, China, European Union, Germany, OECD, United Kingdom, Australia
  • February 9 2017

In the wake of the 2016 elections, we now await the decision as to who will be the "antitrust guard" at the top of the US Department


The Year Ahead: Ten Top Appeals to Watch in 2017
  • McCarthy Tétrault LLP
  • Canada
  • February 8 2017

The coming year will see our highest court decide a host of appeals of interest to Canadian businesses and professions. The Appeals Monitor is pleased


Court Dismisses Alexion's Appeals from Three Separate Orders
  • Borden Ladner Gervais LLP
  • Canada
  • February 1 2017

The Court dismissed Alexion's appeals concerning three separate Orders. The first appeal concerned Prothonotary Aalto's Order allowing the


Costs Awarded at the Higher End of Column IV, with Elevated Costs for Various Factors
  • Borden Ladner Gervais LLP
  • Canada
  • February 1 2017

In this decision on costs, the Court award costs calculated at the top of column IV of Tariff B to the Plaintiff for its successful impeachment action


Unparticularized Allegations Made Pursuant to S. 53 Struck Without Leave to Amend
  • Borden Ladner Gervais LLP
  • Canada
  • February 1 2017

In this case, Apotex started an action to impeach Shire's patent relating to lisdexamfetamine dimesylate. Shire brought a motion to strike portions of


Ongoing Infringement Must be Parsed to Determine Relevant Limitation Periods
  • Bereskin & Parr LLP
  • Canada
  • January 24 2017

In the recent decision of Apotex Inc v AstraZeneca Canada Inc 2017 FCA 9 relating to the drug omeprazole, the Federal Court of Appeal held that in


Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from


Application for Prohibition Granted for Generic Version of Concerta
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Court granted Janssen's application prohibiting the Minister of Health from issuing an NOC to Actavis for its generic version of Concerta. The